Benzinga | Jun 2, 2021 06:47AM EDT

Wells Fargo Maintains Overweight on Abbott Laboratories, Lowers Price Target to $125

Wells Fargo maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $137 to $125.